Brian A Lanman

List of Publications by Year
in descending order

31 papers	2,583 citations	394421 19 h-index	501196 28 g-index
34 all docs	34 docs citations	34 times ranked	3937 citing authors

#	Article	IF	Citations
1	Discovery of a Covalent Inhibitor of KRAS^{G12C} (AMG 510) for the Treatment of Solid Tumors. Journal of Medicinal Chemistry, 2020, 63, 52-65.	6.4	403
2	Half-life extension of peptidic APJ agonists by N-terminal lipid conjugation. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127499.	2.2	7
3	Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRAS^{G12C}. ACS Medicinal Chemistry Letters, 2019, 10, 1302-1308.	2.8	66
4	The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature, 2019, 575, 217-223.	27.8	1,375
5	Discovery of (R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)-a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies. Journal of Medicinal Chemistry, 2019, 62, 1523-1540.	6.4	16
6	Abstract 4455: Discovery of AMG 510, a first-in-human covalent inhibitor of KRASG12Cfor the treatment of solid tumors. , 2019, , .		4
7	Abstract 3090:In vivocharacterization of AMG 510 - a potent and selective KRAS^{G12C}covalent small molecule inhibitor in preclinical KRAS^{G12C}cancer models. , 2019, , .		1
8	Abstract 4484: Discovery and in vitro characterization of AMG 510â€“a potent and selective covalent small-molecule inhibitor of KRAS^{G12C}. , 2019, , .		1
9	Addressing supply issues for natural products in the clinic. Science, 2017, 358, 166-167.	12.6	3
10	Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 6407-6430.	6.4	33
11	Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 408-412.	2.8	22
12	The discovery and optimization of aminooxadiazoles as potent Pim kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 847-855.	2.2	22
13	Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 775-780.	2.2	26
14	The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 834-840.	2.2	28
15	Phosphoinositide-3-kinase inhibitors: Evaluation of substituted alcohols as replacements for the piperazine sulfonamide portion of AMG 511. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5630-5634.	2.2	4
16	Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511. Journal of Medicinal Chemistry, 2012, 55, 7796-7816.	6.4	42
17	Optimization of a Potent, Orally Active S1P₁ Agonist Containing a Quinolinone Core. ACS Medicinal Chemistry Letters, 2012, 3, 74-78.	2.8	16
18	Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases. Journal of Medicinal Chemistry, 2012, 55, 5188-5219.	6.4	43

#	Article	IF	Citations
19	Novel 5- and 6-subtituted benzothiazoles with improved physicochemical properties: Potent S1P1 agonists with in vivo lymphocyte-depleting activity. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 628-633.	2.2	9
20	Quinolinone-based agonists of S1P1: Use of a N-scan SAR strategy to optimize in vitro and in vivo activity. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 527-531.	2.2	15
21	Isoform-selective thiazolo[5,4-b]pyridine S1P1 agonists possessing acyclic amino carboxylate head-groups. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1779-1783.	2.2	8
22	Discovery of AMG 369, a Thiazolo[5,4-b]pyridine Agonist of S1P₁ and S1P₅. ACS Medicinal Chemistry Letters, 2011, 2, 107-112.	2.8	51
23	4-Methoxy-N-[2-(trifluoromethyl)biphenyl-4-ylcarbamoyl]nicotinamide: A Potent and Selective Agonist of S1P₁. ACS Medicinal Chemistry Letters, 2011, 2, 752-757.	2.8	20
24	Discovery of a Potent, S1P₃-Sparing Benzothiazole Agonist of Sphingosine-1-Phosphate Receptor 1 (S1P₁). ACS Medicinal Chemistry Letters, 2011, 2, 102-106.	2.8	19
25	On the Structure of Palau'amine:Â Evidence for the Revised Relative Configuration from Chemical Synthesis. Journal of the American Chemical Society, 2007, 129, 12896-12900.	13.7	73
26	Evaluation of Strategies for the Synthesis of the Guanidine Hemiaminal Portion of Palauâ€™amine. Heterocycles, 2006, 70, 557.	0.7	22
27	Efficient, Stereoselective Synthesis of trans-2,5-Disubstituted Morpholines.. ChemInform, 2004, 35, no.	0.0	0
28	Efficient, Stereoselective Synthesis oftrans-2,5-Disubstituted Morpholines. Organic Letters, 2004, 6, 1045-1047.	4.6	65
29	A Solid-Supported, Enantioselective Synthesis Suitable for the Rapid Preparation of Large Numbers of Diverse Structural Analogues of (â^')-Saframycin A. Journal of the American Chemical Society, 2002, 124, 12969-12971.	13.7	66
30	Synthesis of highly epimerizable N-protected Î±-amino aldehydes of high enantiomeric excess. Tetrahedron Letters, 2000, 41, 1359-1362.	1.4	98
31	Synthesis of C-Protected Î±-Amino Aldehydes of High Enantiomeric Excess from Highly Epimerizable N-Protected Î±-Amino Aldehydes. Organic Letters, 2000, 2, 3337-3340.	4.6	23